Infinitopes Expands Scientific Advisory Board with World-Leading Clinician-Scientist Dr Kristen Hege
Infinitopes, a clinical-stage cancer vaccine Biotechnology company, today announced the appointment of world-leading scientific innovator Dr Kristen Hege to its Scientific Advisory Board (SAB). This strategic appointment comes at a pivotal time after the launch of the VISTA trial, the first dosing in patients of Infinitopes’ lead precision cancer vaccine candidate, ITOP1. ITOP1 is a therapeutic vaccine designed to prevent recurrence in oesophageal cancer – a major area of unmet clinical need.
Infinitopes Doses First Patient With Precision Off-the-Shelf Therapeutic Cancer Vaccine ITOP1
Infinitopes, a clinical-stage biotechnology company developing precision, off-the-shelf therapeutic cancer vaccines for solid tumours, today announced that the first patient has been dosed with ITOP1, the company's lead investigational therapeutic cancer vaccine candidate.
Infinitopes Appoints Immuno-Oncology Pioneer Jo Brewer as Chief Scientific Officer (CSO) to Advance Therapeutic Pipeline From Clinical to Commercialisation
Infinitopes, a biotechnology company developing novel and precision immunotherapy, today announces the appointment of Jo Brewer, PhD, as Chief Scientific Officer and interim Chief Operating Officer. Dr. Brewer, a pioneer and recognised industry leader in cancer immunotherapy and cell therapies, has served as a non-executive director (NED) of the company since March 2025, now joining the executive leadership team at a key inflection point in the company’s growth.
